Lonza Completes Arch Deal; Lists on Singapore Stock Exchange

Lonza has completed its acquisition of Arch Chemicals for $1.4 billion, or $47.20/share. Lonza says it owns more than 90% of Arch’s outstanding shares, and expects to complete the deal through a short-form merger no later than October 21. Upon completion of the merger, Arch will become an indirect, wholly-owned subsidiary of Lonza.   The acquisition creates the largest biocides business, and expands Lonza’s non-pharma life science business, says Lonza CEO Stefan Borgas. “After having built the world's leading pharmaceutical contract...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers